Rest to Overcome Loss and Reduce Risk
RESTore Plus
Developing a Targeted Intervention for Sleep Disturbance in Spousal Bereavement
3 other identifiers
interventional
40
1 country
1
Brief Summary
The purpose of this study is to develop and optimize a targeted behavioral intervention for sleep disturbance among individuals who have recently lost a spouse/long-term cohabitating partner. In the first phase of this study, patient focus groups were conducted to gather information about the unique sleep challenges experienced by spousally bereaved individuals and the kinds of support they would like to receive from a program based on Cognitive Behavior Therapy for Insomnia (CBT-I). In the second phase of the study, a two-arm randomized controlled trial will be conducted to compare changes in sleep and inflammation among participants in the targeted CBT-I intervention to those in an information-only control. Participants will be asked to attend two in-person visits (at baseline and, approx. 8 weeks later, at post-treatment) to provide a blood sample and have vital signs and basic anthropometric measurements (height, weight, waist circumference) taken. After their baseline visit, participants will be randomized into either the targeted CBT-I intervention or the information-only control. The targeted CBT-I intervention will entail 6 online sessions (approx. 50 mins. each) delivered via videoconference by a trained facilitator, once per week over the course of approx. 6 weeks. The information-only control will entail 1 online session (approx. 50 mins.) delivered via videoconference by a trained facilitator. Sleep data (collected via both actigraphy watches and patient self-report sleep diaries) and data on mood, grief, and sleep habits will be collected from participants at three timepoints (baseline, post-treatment, and then again at a 6-month follow-up).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 21, 2023
CompletedStudy Start
First participant enrolled
March 1, 2023
CompletedFirst Posted
Study publicly available on registry
April 7, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2025
CompletedJanuary 21, 2026
January 1, 2026
2.5 years
February 21, 2023
January 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (8)
Feasibility of recruitment
Feasibility of recruitment will be demonstrated by an enrollment benchmark of 2 participants per month.
Approximately 18 months
Feasibility of recruitment
Feasibility of recruitment will also be measured by the proportion of eligible participants who are enrolled (consented) and randomized.
Approx. 18 months
Adherence to the intervention
Adherence to the intervention will be measured by the number of sessions attended by participants.
Approx. 6 months
Treatment-specific retention rates
Treatment-specific retention will be measured by the percentage of participants who complete the post-treatment assessment in each arm.
Approx. 6 months
Acceptability
The acceptability of the intervention will be demonstrated by ≥ 85% completion of the study protocol across the sample.
Approx. 6 months
Attrition
Attrition will be measured at each follow-up visit (post intervention and 6-month follow-up) and will be defined by the percentage of randomized participants who did not attend the follow-up visit. Causes of attrition will be measured by analyzing reasons for participant drop-out as documented over the course of the study.
Approx. 6 months
Treatment-specific acceptability
Treatment-specific acceptability will be measured by preference ratings gathered during the post-treatment debriefing session for each arm.
Approx. 6 months
Preliminary change in sleep disturbance
Using the previously validated Pittsburgh Sleep Quality Index (PSQI), change in sleep disturbance will be assessed from baseline to 1. post-intervention (6-8 weeks later), and a 2. six-month follow-up. Global scores on the PSQI range from 0 to 21, with a higher score indicating more severe sleep disturbance.
Approx. 6 months
Secondary Outcomes (2)
Preliminary change in inflammation
Approx. 8 weeks
Preliminary change in quality of life
Approx. 6 months
Study Arms (2)
Targeted Intervention for Sleep and Bereavement (Targeted CBT-I)
EXPERIMENTALThis intervention consists of 6, 50-60-minute online individual sessions delivered via video conference. Content will include a CBT-I based program adapted to the specific needs of spousally bereaved individuals.
Information-Only Control
PLACEBO COMPARATORThe information-only control consists of 1, 50-60-minute online individual session delivered via video conference. Content will provide basic psychoeducation about sleep and aging.
Interventions
This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.
The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.
Eligibility Criteria
You may qualify if:
- years or older
- Has experienced the loss of a spouse/long-term cohabitating partner (i.e., partner who lived with participant for at least 1 year before passing) within the past 3 months
- Scores 5 or above on the Pittsburgh Sleep Quality Inventory (PSQI; administered by research staff during phone screening call)
- Must have access to an internet-enabled device (e.g., smartphone, computer, tablet) to take part in the online intervention
You may not qualify if:
- Under age 18
- Non-English speakers
- Those with a previously diagnosed sleep disorder (e.g., restless leg syndrome; note: individuals with obstructive sleep apnea (OSA) will be eligible as long as they use a continuous positive airway pressure (CPAP) machine at least 5 days a week for at least 5 hours per day)
- Those who have been taking prescribed sleep medication(s) for 6 months or more
- Those with autoimmune or inflammatory diseases (such as: acute or chronic immune system medical conditions, medications or other conditions that impact immune function (e.g., chronic fatigue syndrome \[CFS\], lupus, rheumatoid arthritis, Sjogren's disease, systemic lupus erythematosus \[SLE\], Hepatitis C, or any other immunosuppressive treatment requiring conditions, per investigator discretion).
- Those who regularly use illegal substances.
- Those who are on medications with major immunological consequences (e.g. steroids)
- Women who are pregnant or nursing
- Those who have been vaccinated in the past two weeks (note: these individuals may simply delay enrollment by two weeks if otherwise eligible)
- Those with significant visual or auditory impairment, medical or psychiatric condition that is unstable, requires immediate treatment or is judged to interfere with study protocol (e.g., substance abuse, psychotic disorder, cognitive disorder, current suicidal ideation)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Northwestern Universitylead
- National Institutes of Health (NIH)collaborator
- National Heart, Lung, and Blood Institute (NHLBI)collaborator
Study Sites (1)
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Masking Details
- Participants will not be informed which arm they have been randomized into. Research assistants will also be blinded to randomization. Only the control and intervention session facilitators and Principal Investigator will be aware of participants' study arm.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Preventive Medicine (Epidemiology)
Study Record Dates
First Submitted
February 21, 2023
First Posted
April 7, 2023
Study Start
March 1, 2023
Primary Completion
August 31, 2025
Study Completion
August 31, 2025
Last Updated
January 21, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ANALYTIC CODE
- Time Frame
- Beginning 9 months and ending 36 months following publication of the primary results.
- Access Criteria
- Data will be available for individual participant data meta-analysis. Proposals may be submitted up to 36 months following publication of the primary results and should be directed to diana.chirinos@northwestern.edu.
Individual participant data that underlie the primary results of the trial after deidentification will be shared.